Clinical Trial Update: TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on tumor-infiltrating lymphocyte therapy combined with pembrolizumab for advanced or metastatic lung cancer (Phase 1/Phase 2), which is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tumor-infiltrating lymphocytes (TIL) therapy

Snippet

Sponsor: Essen Biotech | Conditions: Lung Cancer, Lung Cancer Metastatic | Phase 1, Phase 2 | Status: RECRUITING